Table 3.

Antipsychotic effects of cannabidiol in psychiatric patients and in schizophrenia-like behaviors in animal models (for PPI, see Table 2).

Reference	Results
ANIMAL MODELS
Zuardi et al., 1991	Acute administration of cannabidiol (60 mg/kg) diminishes the stereotyped behavior induced by apomorphine, without promoting catalepsy.
Moreira and Guimaraes, 2005	Acute administration of cannabidiol (30 or 60 mg/kg) attenuates the hyperlocomotion induced by d-amphetamine, without promoting catalepsy.
Malone et al., 2009	Pretreatment with cannabidiol (20 mg/kg) counteracts the Δ9-THC-induced decrease in social interaction.
Long et al., 2010	Chronic treatment with cannabidiol (50 mg/kg, 21 days) attenuates the dexamphetamine-induced hyperlocomotion.
Gururajan et al., 2012	Pretreatment with cannabidiol (3 mg/kg) counteracts the hyperlocomotion and the decrease in social interaction induced by MK-801.
Levin et al., 2012	Acute administration of cannabidiol (1 mg/kg) restores the SHR's deficit in the contextual fear conditioning task.
PSYCHIATRIC PATIENTS
Zuardi et al., 1995	Treatment with cannabidiol for 4 weeks reduced the psychotic symptoms in one schizophrenia patient.
Zuardi et al., 2009	Treatment with cannabidiol for 4 weeks, in addition to their usual treatment, reduced the psychotic symptoms in six patients with Parkinson's disease without worsening their motor function.
Leweke et al., 2012	Treatment with cannabidiol for 4 weeks reduced the schizophrenia symptoms in 21 schizophrenia patients, in a way non-inferior to the antipsychotic amisulpride. Cannabidiol induced fewer side effects than amisulpride.
GW Pharmaceuticals, 2015	Proof of concept study including 88 schizophrenia patients. Treatment with cannabidiol for 6 weeks, in addition to their usual antipsychotic medication, reduced the schizophrenia symptoms without inducing serious adverse events.

MK-801, dizocilpine; SHR, spontaneously hypertensive rats; ${\Delta }_{-}^9$THC, delta-9-tetrahydrocannabinol.